Literature DB >> 1595533

Adenosine versus verapamil in the treatment of supraventricular tachycardia: a randomized double-crossover trial.

M A Hood1, W M Smith.   

Abstract

The safety and efficacy of verapamil and adenosine in the acute termination of supraventricular tachycardia were compared in a randomized double-crossover trial. Of 32 eligible patients with either spontaneous or induced narrow complex tachycardia, seven (22%) patients experienced conversion to sinus rhythm with carotid sinus massage. The other 25 patients were randomly assigned to receive either adenosine (n = 14) or verapamil (n = 11). Relative drug efficacies were 100% for adenosine versus 73% for verapamil, p = NS. Adenosine given at less than or equal to 120 micrograms/kg caused conversion in 12 (86%) of 14 patients. The other two patients required 20 mg adenosine for conversion. After conversion the systolic blood pressure increased significantly in the adenosine group but not in the verapamil group. Reinitiation of tachycardia occurred in two (14%) of 14 patients randomized to the adenosine group. Serious adverse hemodynamic effects were observed in one (9%) of 11 patients randomized to verapamil. The incidence of conversion arrhythmias was similar in both treatment groups (adenosine 57%, verapamil 50%, p = NS).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1595533     DOI: 10.1016/0002-8703(92)90807-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  14 in total

1.  Dose and rate-dependent effects of adenosine on atrial action potential duration in humans.

Authors:  J Tebbenjohanns; B Schumacher; D Pfeiffer; W Jung; B Lüderitz
Journal:  J Interv Card Electrophysiol       Date:  1997-02       Impact factor: 1.900

2.  Intravenous diltiazem hydrochloride rather than verapamil for resistant paroxysmal supraventricular tachycardia.

Authors:  T J Peitz
Journal:  West J Med       Date:  1993-11

3.  Prehospital use of adenosine by ambulance services in the Netherlands: Daily practice, literature overview and practical recommendations.

Authors:  R Adams; V Bon
Journal:  Neth Heart J       Date:  2003-05       Impact factor: 2.380

4.  Executive Summary: European Heart Rhythm Association Consensus Document on the Management of Supraventricular Arrhythmias: Endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE).

Authors:  Demosthenes G Katritsis; Giuseppe Boriani; Francisco G Cosio; Pierre Jais; Gerhard Hindricks; Mark E Josephson; Roberto Keegan; Bradley P Knight; Karl-Heinz Kuck; Deirdre A Lane; Gregory Yh Lip; Helena Malmborg; Hakan Oral; Carlo Pappone; Sakis Themistoclakis; Kathryn A Wood; Kim Young-Hoon; Carina Blomström Lundqvist
Journal:  Arrhythm Electrophysiol Rev       Date:  2016

5.  Clinical Profile of Cardiac Arrhythmias in Children Attending the Out Patient Department of a Tertiary Paediatric Care Centre in Chennai.

Authors:  Sarala Premkumar; Premkumar Sundararajan; Thangavelu Sangaralingam
Journal:  J Clin Diagn Res       Date:  2016-12-01

Review 6.  Is there a future for antiarrhythmic drug therapy?

Authors:  P G Guerra; M Talajic; D Roy; M Dubuc; B Thibault; S Nattel
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

7.  Inhibition of adenosine deaminase and administration of adenosine increase hypoxia induced ventricular ectopy.

Authors:  R J Leone; G F Merrill
Journal:  Basic Res Cardiol       Date:  1995 May-Jun       Impact factor: 17.165

8.  Adenosine-tri-phosphate treatment for supraventricular tachycardia in infants.

Authors:  D De Wolf; G Rondia; H Verhaaren; D Matthys
Journal:  Eur J Pediatr       Date:  1994-11       Impact factor: 3.183

9.  Adenosine triphosphate treatment for supraventricular tachycardia in infants.

Authors:  D De Wolf; G Rondia; H Verhaaren; D Matthys
Journal:  Eur J Pediatr       Date:  1994-09       Impact factor: 3.183

Review 10.  Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia.

Authors:  Samer Alabed; Ammar Sabouni; Rui Providencia; Edmond Atallah; Mohammed Qintar; Timothy Ja Chico
Journal:  Cochrane Database Syst Rev       Date:  2017-10-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.